These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21297383)

  • 1. Androgen regulation of prostate cancer: where are we now?
    Corona G; Baldi E; Maggi M
    J Endocrinol Invest; 2011 Mar; 34(3):232-43. PubMed ID: 21297383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects.
    Corona G; Gacci M; Baldi E; Mancina R; Forti G; Maggi M
    J Sex Med; 2012 Mar; 9(3):887-902. PubMed ID: 22248394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate diseases--role of sex steroids and their inhibitors.
    Welén K; Damber JE
    Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
    Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
    Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
    Kumagai J; Hofland J; Erkens-Schulze S; Dits NF; Steenbergen J; Jenster G; Homma Y; de Jong FH; van Weerden WM
    Prostate; 2013 Nov; 73(15):1636-50. PubMed ID: 23996639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
    Nishiyama T
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Castration-recurrent prostate cancer is not androgen-independent.
    Mohler JL
    Adv Exp Med Biol; 2008; 617():223-34. PubMed ID: 18497046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of the development of androgen independence in prostate cancer.
    So A; Gleave M; Hurtado-Col A; Nelson C
    World J Urol; 2005 Feb; 23(1):1-9. PubMed ID: 15770516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
    Sabnis NG; Miller A; Titus MA; Huss WJ
    Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
    Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
    Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.
    Eikenberry SE; Nagy JD; Kuang Y
    Biol Direct; 2010 Apr; 5():24. PubMed ID: 20406442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
    Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
    Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.
    Fiandalo MV; Wilton J; Mohler JL
    Int J Biol Sci; 2014; 10(6):596-601. PubMed ID: 24948872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
    Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
    Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
    Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative approaches to prevent androgen action in prostate cancer: are we there yet?
    Elbanna M; Heemers HV
    Discov Med; 2014 May; 17(95):267-74. PubMed ID: 24882718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.